This is a TROPION news story, published by Yahoo Finance, that relates primarily to AstraZeneca news.
For more TROPION news, you can click here:
more TROPION newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
key lung cancer trials. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Lung01 trial news, lung cancer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cancer drugsReuters
•77% Informative
The TROPION -Lung01 trial "did not reach statistical significance", AstraZeneca said.
The late-stage trial has been closely watched by investors and by analysts.
The drug, known as Dato-DXd, could potentially be another best-selling medicine for the company.
Previous data releases related to the trial have knocked shares.
VR Score
89
Informative language
99
Neutral language
1
Article tone
formal
Language
English
Language complexity
62
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links